异噁唑基青霉素类药物的药代动力学药物相互作用:系统综述与实用指南
该系统综述检索了截至2025年11月Pubmed和Embase中关于氯唑西林、双氯西林、氟氯西林和苯唑西林等异噁唑基青霉素类药代动力学药物相互作用的人类研究,共纳入51篇文章,涉及33种潜在受害药物。多数研究报道合用异噁唑基青霉素类期间药物暴露和/或疗效降低,提示CYP酶、UGT酶和P-糖蛋白诱导可能是最可能机制,但研究设计质量和终点异质性限制了机制阐明。
要点
- 异噁唑基青霉素类与治疗窗窄且经广泛代谢的药物合用时,可能发生有临床意义的相互作用。
- 多数报告显示合用期间受害药物暴露和/或疗效降低,机制可能涉及CYP、UGT和P-gp诱导。
- 现有证据以临床观察为主,研究设计质量和终点异质性限制相互作用机制和临床相关性的明确。
核心结论
- 异噁唑基青霉素类与经广泛代谢且治疗窗窄的药物合用时,临床医生应警惕潜在的有临床意义的药代动力学相互作用。
研究设计与样本
- 系统检索Pubmed和Embase截至2025年11月报告人类异噁唑基青霉素类潜在药代动力学相互作用的文章,共纳入51篇,包括24篇病例报告或病例系列、16项回顾性队列研究和11项前瞻性或交叉研究。
主要发现
- 共识别33种潜在受害药物,多数纳入研究报告合用异噁唑基青霉素类期间药物暴露和/或疗效降低。
- 最可能机制涉及诱导细胞色素P450酶、二磷酸葡萄糖醛酸转移酶和P-糖蛋白,但因研究设计质量和终点异质性未能完全阐明确切机制。
临床怎么用
- 临床医生在合用异噁唑基青霉素类与治疗窗窄且经广泛代谢的药物时,应意识到潜在的有临床意义的相互作用。
局限性
- 纳入研究以临床观察为主,研究设计质量和终点异质性限制了相互作用机制和临床相关性的充分阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent years have seen a notable increase in the number of publications concerning pharmacokinetic drug-drug interactions involving the isoxazolyl penicillins cloxacillin, dicloxacillin, flucloxacillin and oxacillin. Given that the findings predominantly rely on clinical observations, the interaction mechanisms and their clinical relevance remain insufficiently elucidated, thereby posing challenges for clinicians in managing these interactions. The aim of this literature review was to provide an overview of all reported pharmacokinetic drug-drug interactions involving isoxazolyl penicillins and to evaluate the plausible interaction mechanisms. We systematically searched articles reporting potential pharmacokinetic drug-drug interactions involving isoxazolyl penicillins in humans up to November 2025 in Pubmed and Embase. The quality of the articles was assessed using a self-developed risk of bias assessment tool. A modified drug-drug interaction probability assessment tool was used to objectively evaluate the probability of the reported potential interactions. A total of 33 potential victim drugs were identified across 51 articles, comprising 24 case reports or case series, 16 retrospective cohort studies and 11 prospective or crossover studies. Most of the included studies report a decreased exposure and/or efficacy of drugs during concomitant treatment with isoxazolyl penicillins. Although pointing towards induction of cytochrome P450 enzymes, diphosphate-glucuronosyltransferase enzymes and P-glycoprotein as most plausible mechanism for most interactions, the exact interaction mechanisms could not be fully elucidated due to the quality of the study designs and heterogeneity in endpoints. Clinicians should be aware of a potential clinically relevant interaction when combining isoxazolyl penicillins with drugs with a small therapeutic window that undergo extensive metabolism.
引用
- Wortman JM, Leegwater E, Wilms EB, et al. Pharmacokinetic drug-drug interactions with flucloxacillin and other isoxazolyl penicillins: A systematic literature review and practical guide. Br J Clin Pharmacol. 2026. PMID: 41789926. doi:10.1002/bcp.70511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。